WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > PSC Biotech
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Industrial Impact, Medical
Globenewswire | April 19, 2023
Merck known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. “At Merck, we are committed to delivering on our purpose to save and improve lives and continue to identify and secure opportunities where compelling scienc...
Cell and Gene Therapy, Industrial Impact
Evaxion Biotech A/S | January 23, 2023
Evaxion Biotech A/S, a leading clinical-stage biotechnology firm focused on the development of AI-driven immunotherapies, recently announced that FDA has granted fast-track designation for the Company's customized cancer therapy, EVX-01, in conjunction with KEYTRUDA®. In December 2022, Evaxion gained FDA clearance to proceed with its phase 2b clinical test, where patients with metastatic melanoma are given EVX-01 in combination with KEYTRUDA®. In addition, Evaxion ob...
Tevogen Bio | August 11, 2020
Tevogen Bio believes that its investigational highly purified antigen-specific T cell therapy holds promise in the treatment of viral infections including COVID-19 and Influenza A. This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr. Flomenberg's expertise in immunology, histocompatibility and pioneering work in the immunology of stem cell transplantation. Tevogen Bio announces a joint partnership with renowned bone-marrow transplant expert Neal Flomenb...
FierceBiotech | February 06, 2020
Just months after collecting $90 million to support the launch of its compact DNA sequencing hardware, GenapSys has raised another $75 million to finance its global expansion with its eyes set on the Asia-Pacific market and the expanding coronavirus outbreak. The company’s high-throughput sequencer—which sits on a tabletop and weighs less than 10 pounds—is being launched in South Korea, Singapore, Japan and China as part of more than 25 recently inked distribution deals....
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE